Essex Woodlands Fund IX, L.P.

Average Profitability
21.16%
Insider Buys Quantity
4
Insider Buys Sum
$37.52M
Insider Sells Quantity
10
Insider Sells Sum
$53.48M

Insider Activity of Essex Woodlands Fund IX, L.P.

The largest purchase of all time was on 2018-06-25 and amounted to 16864066 shares of EyePoint Pharmaceuticals, Inc. for $21.33M.

The largest sale of all time was on 2017-11-20 and amounted to 2300000 shares of AxoGen, Inc. for $45.4M.

Biography of Essex Woodlands Fund IX, L.P.

No biography is available at this moment.

2023-09-01SaleEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
20,000
0.054%
$9.90$197,982+10.36%
2023-08-31SaleEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
78,495
0.2319%
$10.24$804,061+16.75%
2023-08-30SaleEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
60,976
0.1736%
$10.92$666,147+4.57%
2023-08-29SaleEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
87,854
0.2561%
$10.75$944,225+10.14%
2023-08-28SaleEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
60,858
0.1749%
$11.71$712,653-0.73%
2023-08-25SaleEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
84,656
0.2354%
$11.00$931,327+3.01%
2023-08-24SaleEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
139,280
0.3637%
$11.17$1.56M+1.22%
2023-08-23SaleEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
121,103
0.3695%
$13.05$1.58M-0.26%
2023-08-22SaleEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
46,778
0.1337%
$14.62$683,834-20.35%
2021-12-15PurchaseVenus Concept Inc.
VERO
10 percent owner
3.92M
0.4649%
$1.25$4.9M-50.47%
2020-03-18PurchaseVenus Concept Inc.
VERO
10 percent owner
1.08M
$1.68$1.82M+13.62%
2018-06-25PurchaseEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
16.86M
19.9567%
$1.26$21.33M+13.99%
2018-03-28PurchaseEyePoint Pharmaceuticals, Inc.
EYPT
10 percent owner
8.61M
19.384%
$1.10$9.47M+107.48%
2017-11-20SaleAxoGen, Inc.
AXGN
10 percent owner
2.3M
5.5203%
$19.74$45.4M+51.03%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.